Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash & Equivalents (2016 - 2025)

CorMedix has reported Cash & Equivalents over the past 16 years, most recently at $144.8 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $144.8 million for Q4 2025, up 256.29% from a year ago — trailing twelve months through Dec 2025 was $144.8 million (up 256.29% YoY), and the annual figure for FY2025 was $144.8 million, up 256.29%.
  • Cash & Equivalents reached $144.8 million in Q4 2025 per CRMD's latest filing, up from $48.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $159.3 million in Q2 2025 and bottomed at $19.7 million in Q2 2023.
  • Median Cash & Equivalents over the past 5 years was $43.4 million (2022), compared with a mean of $55.1 million.
  • The largest annual shift saw Cash & Equivalents surged 599.08% in 2021 before it plummeted 70.38% in 2022.
  • Over 5 years, Cash & Equivalents stood at $53.3 million in 2021, then dropped by 19.07% to $43.1 million in 2022, then increased by 1.15% to $43.6 million in 2023, then dropped by 6.85% to $40.7 million in 2024, then surged by 256.29% to $144.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for CRMD at $144.8 million in Q4 2025, $48.5 million in Q3 2025, and $159.3 million in Q2 2025.